Evolving Options for HBV Therapy: Navigating the New Treatment Landscape

In this live CME/CE/CPE-certified Webinar, pose questions and gain expert advice on integrating the latest HBV therapies into your clinical practice.


  • Program Overview and Baseline Assessment
  • Goals of Therapy
    • Understanding benefits and risks of long-term therapy
  • When and What to Start
    • Surveying the treatment landscape and current guidelines
  • Choosing Among Nucleos(t)ide Analogues
    • Advantages and disadvantages of each regimen in this new treatment era
    • Individualizing HBV treatment plans to maximize efficacy and tolerability
  • Question and Answer Session


Date / Time
Event Details


Program Director
Norah Terrault, MD, MPH

Professor of Medicine and Surgery
Director, Viral Hepatitis Center
Division of Gastroenterology
University of California, San Francisco
San Francisco, California

Robert S. Brown, Jr., MD, MPH

Gladys and Roland Harriman Professor of Medicine
Vice Chair,
Transitions of Care
Clinical Chief, Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Natalie Bzowej, MD, PhD

Director, Clinical Hepatology Research
Department of Liver Transplantation
California Pacific Medical Center
San Francisco, California

Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Tram Tran, MD

Medical Director of Liver Transplant
Comprehensive Transplant Center
Cedars Sinai Medical Center
Professor of Medicine
Division of Gastroenterology
Geffen UCLA School of Medicine
Los Angeles, California


Goal Statement
The goal of this activity is to improve clinicians’ competence in objectively evaluating the differences and similarities among available HBV agents and in selecting optimal therapy for each individual patient.

Target Audience
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with chronic hepatitis B.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply the latest treatment guidelines when making optimized management decisions for chronic hepatitis B
  • Formulate individualized HBV treatment plans that maximize efficacy and tolerability for each patient
  • Integrate recently approved HBV therapies into patient management strategies


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement 
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
This educational activity for .7 contact hour is provided by Postgraduate Institute for Medicine.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Pharmacist Continuing Education
ACPE logo
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for .75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0809-9999-17-916-L01-P.

Type of Activity

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.